DA/ZtmKini |
percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time |
myelin oligodendrocyte glycoprotein (200 ul) |
Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. |
central nervous system integrity trait |
not specified |
63 days-105 days |
8 |
87.5 |
% |
|
|
in vivo visual assessment |
whole animal |
0.0 |
injection |
40 |
days |
range 31 to 40 days |
|
68201 |
829 |
DA.ACI-(D10Rat2-D10Rat6) |
percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time |
myelin oligodendrocyte glycoprotein (200 ul) |
Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. |
central nervous system integrity trait |
not specified |
63 days-105 days |
8 |
87.5 |
% |
|
|
in vivo visual assessment |
whole animal |
0.0 |
injection |
40 |
days |
range 31 to 40 days |
|
68207 |
829 |
DA.ACI-(D10Rat15-D10Rat29) |
percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time |
myelin oligodendrocyte glycoprotein (200 ul) |
Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. |
central nervous system integrity trait |
not specified |
63 days-105 days |
8 |
37.5 |
% |
|
|
in vivo visual assessment |
whole animal |
0.0 |
injection |
40 |
days |
range 31 to 40 days |
|
68204 |
829 |
DA.ACI-(D10Rat10-D10Rat142) |
percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time |
myelin oligodendrocyte glycoprotein (200 ul) |
Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. |
central nervous system integrity trait |
not specified |
63 days-105 days |
7 |
71.4 |
% |
|
|
in vivo visual assessment |
whole animal |
0.0 |
injection |
40 |
days |
range 31 to 40 days |
|
68219 |
829 |
DA/ZtmKini |
percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time |
myelin oligodendrocyte glycoprotein (20 ug) |
Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. |
central nervous system integrity trait |
male |
103 days-131 days |
8 |
87.5 |
% |
|
|
in vivo visual assessment |
|
0.0 |
intradermal injection |
40 |
days |
from p.i. day 7 |
|
68717 |
839 |
DA/ZtmKini |
percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time |
myelin oligodendrocyte glycoprotein (20 ug) |
Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. |
central nervous system integrity trait |
male |
103 days-131 days |
8 |
87.5 |
% |
|
|
in vivo visual assessment |
|
0.0 |
intradermal injection |
40 |
days |
from p.i. day 7 |
|
68709 |
839 |
DA/ZtmKini |
percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time |
myelin oligodendrocyte glycoprotein (200 ul) |
Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. |
central nervous system integrity trait |
not specified |
63 days-105 days |
16 |
81.3 |
% |
|
|
in vivo visual assessment |
whole animal |
0.0 |
injection |
40 |
days |
range 31 to 40 days |
|
68225 |
829 |
DA.ACI-(D10Rat2-D10Rat29)/Kini |
percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time |
myelin oligodendrocyte glycoprotein (200 ul) |
Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. |
central nervous system integrity trait |
not specified |
63 days-105 days |
8 |
37.5 |
% |
|
|
in vivo visual assessment |
whole animal |
0.0 |
injection |
40 |
days |
range 31 to 40 days |
|
68732 |
829 |
DA.ACI-(D10Rat15-D10Rat29) |
percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time |
myelin oligodendrocyte glycoprotein (200 ul) |
Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. |
central nervous system integrity trait |
not specified |
63 days-105 days |
12 |
8.3 |
% |
|
|
in vivo visual assessment |
whole animal |
0.0 |
injection |
40 |
days |
range 31 to 40 days |
|
68195 |
829 |
DA/ZtmKini |
percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time |
myelin oligodendrocyte glycoprotein (200 ul) |
Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. |
central nervous system integrity trait |
not specified |
63 days-105 days |
16 |
56.3 |
% |
|
|
in vivo visual assessment |
whole animal |
0.0 |
injection |
40 |
days |
range 31 to 40 days |
|
68210 |
829 |
DA.ACI-(D10Rat219-D10Rat29) |
percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time |
myelin oligodendrocyte glycoprotein (200 ul) |
Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. |
central nervous system integrity trait |
not specified |
63 days-105 days |
10 |
40.0 |
% |
|
|
in vivo visual assessment |
whole animal |
0.0 |
injection |
40 |
days |
range 31 to 40 days |
|
68216 |
829 |
DA.ACI-(D10Rat12-D10Rat144) |
percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time |
myelin oligodendrocyte glycoprotein (200 ul) |
Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. |
central nervous system integrity trait |
not specified |
63 days-105 days |
13 |
38.5 |
% |
|
|
in vivo visual assessment |
whole animal |
0.0 |
injection |
40 |
days |
range 31 to 40 days |
relap, % |
68222 |
829 |
DA.ACI-(D10Rat15-D10Rat29) |
percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time |
myelin oligodendrocyte glycoprotein (200 ul) |
Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. |
central nervous system integrity trait |
not specified |
63 days-105 days |
13 |
30.8 |
% |
|
|
in vivo visual assessment |
whole animal |
0.0 |
injection |
40 |
days |
range 31 to 40 days |
relap, % |
68228 |
829 |
DA.ACI-(D10Rat2-D10Rat29)/Kini |
percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time |
myelin oligodendrocyte glycoprotein (20 ug) |
Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. |
central nervous system integrity trait |
male |
103 days-131 days |
1 |
0.0 |
% |
|
|
in vivo visual assessment |
|
0.0 |
intradermal injection |
40 |
days |
from p.i. day 7 |
|
68729 |
839 |
DA/ZtmKini |
percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time |
myelin oligodendrocyte glycoprotein (20 ug) |
Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. |
central nervous system integrity trait |
male |
103 days-131 days |
6 |
50.0 |
% |
|
|
in vivo visual assessment |
|
0.0 |
intradermal injection |
40 |
days |
from p.i. day 7 |
CMO:0001402 |
68713 |
839 |
DA/ZtmKini |
percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time |
myelin oligodendrocyte glycoprotein (200 ul) |
Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. |
central nervous system integrity trait |
not specified |
63 days-105 days |
10 |
70.0 |
% |
|
|
in vivo visual assessment |
whole animal |
0.0 |
injection |
40 |
days |
range 31 to 40 days |
|
68198 |
829 |
DA.ACI-(D10Rat15-D10Rat29) |
percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time |
myelin oligodendrocyte glycoprotein (200 ul) |
Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. |
central nervous system integrity trait |
not specified |
63 days-105 days |
10 |
30.0 |
% |
|
|
in vivo visual assessment |
whole animal |
0.0 |
injection |
40 |
days |
range 31 to 40 days |
|
68213 |
829 |
DA.ACI-(D10Rat2-D10Rat29)/Kini |
percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time |
myelin oligodendrocyte glycoprotein (200 ul) |
Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. |
central nervous system integrity trait |
not specified |
63 days-105 days |
7 |
0.0 |
% |
|
|
in vivo visual assessment |
whole animal |
0.0 |
injection |
40 |
days |
range 31 to 40 days |
|
68733 |
829 |
DA/ZtmKini |
percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time |
myelin oligodendrocyte glycoprotein (20 ug) |
Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. |
central nervous system integrity trait |
male |
103 days-131 days |
11 |
91.0 |
% |
|
|
in vivo visual assessment |
|
0.0 |
intradermal injection |
40 |
days |
from p.i. day 7 |
CMO:0001402 |
68135 |
839 |
DA.ACI-(D10Rat219-D10Rat29) |
percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time |
myelin oligodendrocyte glycoprotein (200 ul) |
Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. |
central nervous system integrity trait |
not specified |
63 days-105 days |
16 |
25.0 |
% |
|
|
in vivo visual assessment |
whole animal |
0.0 |
injection |
40 |
days |
range 31 to 40 days |
expressed as a fraction of total number of animals |
68231 |
829 |
DA.ACI-(D10Rat2-D10Rat29)/Kini |
percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time |
myelin oligodendrocyte glycoprotein (20 ug) |
Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. |
central nervous system integrity trait |
male |
103 days-131 days |
3 |
0.0 |
% |
|
|
in vivo visual assessment |
|
0.0 |
intradermal injection |
40 |
days |
from p.i. day 7 |
|
68721 |
839 |